Sotatercept
Clinical data
Other namesACE-011, MK-7962-020
ATC code
  • None
Identifiers
CAS Number
DrugBank
UNII
KEGG

Sotatercept (ACE-011, MK-7962-020) is a activin signaling inhibitor therapy drug being developed for pulmonary arterial hypertension.[1][2][3][4] It was initially developed to increase bone density[5] and has also been developed for anemia[6][7][8] and multiple myeloma.[9]

References

  1. ↑ Joshi, Sachindra R.; Liu, Jun; Bloom, Troy; Karaca Atabay, Elif; Kuo, Tzu-Hsing; Lee, Michael; Belcheva, Elitza; Spaits, Matthew; Grenha, Rosa; Maguire, Michelle C.; Frost, Jeffrey L.; Wang, Kathryn; Briscoe, Steven D.; Alexander, Mark J.; Herrin, Brantley R.; Castonguay, Roselyne; Pearsall, R. Scott; Andre, Patrick; Yu, Paul B.; Kumar, Ravindra; Li, Gang (12 May 2022). "Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension". Scientific Reports. 12 (1): 7803. Bibcode:2022NatSR..12.7803J. doi:10.1038/s41598-022-11435-x. ISSN 2045-2322. PMC 9098455. PMID 35551212.
  2. ↑ Humbert, Marc; McLaughlin, Vallerie; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; Hoeper, Marius M.; Preston, Ioana R.; Souza, Rogerio; Waxman, Aaron; Escribano Subias, Pilar; Feldman, Jeremy; Meyer, Gisela; Montani, David; Olsson, Karen M.; Manimaran, Solaiappan; Barnes, Jennifer; Linde, Peter G.; de Oliveira Pena, Janethe; Badesch, David B. (1 April 2021). "Sotatercept for the Treatment of Pulmonary Arterial Hypertension". New England Journal of Medicine. 384 (13): 1204–1215. doi:10.1056/NEJMoa2024277. ISSN 0028-4793. PMID 33789009.
  3. ↑ "Role of Sotatercept in Management of Pulmonary Arterial Hypertension: The STELLAR Trial". American College of Cardiology.
  4. ↑ Humbert, Marc; McLaughlin, Vallerie; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; Hoeper, Marius M.; Preston, Ioana R.; Souza, Rogerio; Waxman, Aaron B.; Ghofrani, Hossein-Ardeschir; Subias, Pilar Escribano; Feldman, Jeremy; Meyer, Gisela; Montani, David; Olsson, Karen M.; Manimaran, Solaiappan; Pena, Janethe de Oliveira; Badesch, David B. (1 January 2022). "Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension". European Respiratory Journal. 61 (1). doi:10.1183/13993003.01347-2022. ISSN 0903-1936. PMC 9816418. PMID 36041750.
  5. ↑ Sherman, Matthew L.; Borgstein, Niels G.; Mook, Louisa; Wilson, Dawn; Yang, Yijun; Chen, Nianhang; Kumar, Ravindra; Kim, Kenneth; Laadem, Abderrahmane (November 2013). "Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women". The Journal of Clinical Pharmacology. 53 (11): 1121–1130. doi:10.1002/jcph.160. ISSN 0091-2700. PMID 23939631.
  6. ↑ Lan, Zehao; Lv, Zhaohua; Zuo, Wanyun; Xiao, Yichao (September 2023). "From bench to bedside: The promise of sotatercept in hematologic disorders". Biomedicine & Pharmacotherapy. 165: 115239. doi:10.1016/j.biopha.2023.115239. PMID 37516019.
  7. ↑ Komrokji, Rami; Garcia-Manero, Guillermo; Ades, Lionel; Prebet, Thomas; Steensma, David P; Jurcic, Joseph G; Sekeres, Mikkael A; Berdeja, Jesus; Savona, Michael R; Beyne-Rauzy, Odile; Stamatoullas, Aspasia; DeZern, Amy E; Delaunay, Jacques; Borthakur, Gautam; Rifkin, Robert; Boyd, Thomas E; Laadem, Abderrhamane; Vo, Bond; Zhang, Jennie; Puccio-Pick, Marie; Attie, Kenneth M; Fenaux, Pierre; List, Alan F (February 2018). "Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial". The Lancet Haematology. 5 (2): e63–e72. doi:10.1016/S2352-3026(18)30002-4. PMID 29331635.
  8. ↑ Raje, Noopur; Vallet, Sonia (1 October 2010). "Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss". Current Opinion in Molecular Therapeutics. 12 (5): 586–597. ISSN 2040-3445. PMID 20886391.
  9. ↑ Abdulkadyrov, Kudrat M.; Salogub, Galina N.; Khuazheva, Nuriet K.; Sherman, Matthew L.; Laadem, Abderrahmane; Barger, Rachel; Knight, Robert; Srinivasan, Shankar; Terpos, Evangelos (June 2014). "Sotatercept in patients with osteolytic lesions of multiple myeloma". British Journal of Haematology. 165 (6): 814–823. doi:10.1111/bjh.12835. PMC 4312883. PMID 24650009.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.